Serina Therapeutics (NYSEAMERICAN:SER) Stock Price Down 1% – Should You Sell?

Serina Therapeutics, Inc. (NYSEAMERICAN:SER)’s stock price fell 1% on Friday . The company traded as low as $1.98 and last traded at $2.07. 44,323 shares changed hands during mid-day trading, a decline of 4% from the average session volume of 46,056 shares. The stock had previously closed at $2.09.

Wall Street Analysts Forecast Growth

Separately, BTIG Research initiated coverage on shares of Serina Therapeutics in a report on Wednesday, July 1st. They issued a “buy” rating and a $8.00 price objective for the company. One investment analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $8.00.

Serina Therapeutics Price Performance

The company has a debt-to-equity ratio of 0.24, a quick ratio of 4.18 and a current ratio of 4.18. The stock has a market cap of $31.05 million, a price-to-earnings ratio of -1.03 and a beta of 1.11. The firm’s fifty day simple moving average is $1.93.

Serina Therapeutics (NYSEAMERICAN:SER) last released its earnings results on Thursday, May 14th. The company reported ($0.58) earnings per share (EPS) for the quarter.

About Serina Therapeutics

Serina Therapeutics, Inc, a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson’s disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson’s disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc was founded in 2006 and is based in Huntsville, Alabama.